Home Sectors Consumer Cyclical Buy or Sell: Monarch Casino And Resort (NASDAQ: MCRI)

Buy or Sell: Monarch Casino And Resort (NASDAQ: MCRI)

20
0
SHARE

Monarch Casino And Resort is in the consumer cyclical sector and is part of the travel and leisure industry. The company CEO is John Farahi. Monarch Casino and Resort Inc owns and operates the Atlantis Casino Resort Spa, a hotel or casino facility in Reno, Nevada; the Monarch Casino Black Hawk in Black Hawk, Colorado and real estate proximate to the Atlantis and Monarch Casino Black Hawk.

Previous Intraday Trading Performance:

The MCRI stock showed a previous change of 0.37% with an open at 43.10 and a close of 43.45. It reached an intraday high of 44.02 and a low of 42.69.

SeekingAlpha:  Union Gaming pulls back on Monarch Casino & Resort

Liquidity:

The stock has a market cap of $778.6m with 17.9m shares outstanding, of which the float is 14.8m shares. Trading volume reached 50,362 shares compared to its average volume of 37,838 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Monarch Casino And Resort shares returned -1.94% and in the past 30 trading days it returned 2.45%. Over three months, it changed 11.27%. In one year it has changed -0.55% and within that year its 52-week high was 49.63 and its 52-week low was 34.45. MCRI stock is 26.12% above its 52 Week Low.

Our calculations show a 200 day moving average of 43.74 and a 50 day moving average of 42.15. Currently MCRI stock is trading -0.67% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

SeekingAlpha:  Union Gaming pulls back on Monarch Casino & Resort

Earnings:

The last annual fiscal EPS for the company was reported at 1.83 that ended on 31st of December 2018, which according to the previous close, that is a PE of 23.74. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.42. The TTM EPS is 1.83, which comes to a TTM PE of 23.74. Historically, the PE high was 35.70 and the PE low was 10.60. If the stock reached its PE low, that would represent a price of 19.40, which is a decrease of -55.35%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.39
09-30-2018:  0.58
06-30-2018:  0.50
03-31-2018:  0.36

Base on our calculations, the intrinsic value per share is 93.19, which means it is possibly undervalued and has a margin of safety of 53.37%

Indicators to Watch:

Based on the latest filings, there is 17.30% of insider ownership and 91.10% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.22

SeekingAlpha:  Momenta Pharmaceuticals beats by $0.39, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 12.01%, return on assets is 8.66%, profit margin is 14.78%, price-to-sales is 3.36 and price-to-book is 2.64.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 4  :Past Performance Score
 4  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here